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Abstract 
In normal condition, the heart obtains more than two-thirds of the energy 
from oxidative metabolism of the long chain fatty acids, although a wide 
variety of substrates such as glucose, lactate, keton bodies and aminoacids 
are also utilized. In ischemic myocardium, on the other hand, oxidative 
metabolism of free fatty acid is suppressed and anaerobic glucose 
metabolism play a major role for residual oxidative metabolism. Therefore, 
metabolic imaging can be an important technique for the assessment of 
various cardiac diseases and conditions. In SPECT, up to the present, several 
iodinated fatty acid traces have been introduced and studied. Of these, I-123 
labeled 15-(p-iodophenyl)3R, S-methylpentadecanoic acid (BMIPP) has 
been the most commonly used tracers in clinical studies, especially in some 
of the European countries and Japan. In this review article the 
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 characterization of the several fatty acid tracers for SPECT are described and 




The cardiac muscle metabolizes a variety of substrates by selecting 
appropriate ones available in the particular myocardial condition. In normal 
condition, fatty acids and glucose are the most preferred substrate for energy 
production, followed by lactate, amino acids, keton bodies. Approximately 
two-thirds or more of the total energy produced by myocardium is derived 
from fatty acid oxidation and the most of the remaining energy is covered by 
the glucose metabolism. Both fatty acid and glucose are catabolized to 
acetyl-COA through beta-oxidation and glycolysis and the metabolite is 
oxidized in the tricarboxylic acid (TCA) cycle. In various pathological 
conditions the myocardial metabolism can be changed significantly, for 
instance, in ischemia, oxidative metabolism of free fatty acid is decreased 
because ß-oxidation of fatty acid in mitochondria requires a large amount of 
oxygen, and glucose becomes the preferred substrate for anaerobic 
glycolysis that requires less oxygen consumption [1, 2]. Therefore, imaging 
tracers that permit direct assessment of myocardial metabolism are desired 
to evaluate the pathophysiological changes in various heart disease. Current 
available tracers for metabolic imaging are several fatty acid tracers, 
18F-FDG for the evaluation of glucose metabolism, and 11C-acetate for the 
assessment of oxygen consumption. Of these tracers, only 123I-labeled fatty 
acid tracers are currently available for SPECT imaging. 
 
Myocardial fatty acid uptake and metabolism 
Due to hydrophobic nature of fatty acids, they are delivered to the heart by 
binding to plasma albumin or lipoproteins. After dissociating from albumin 
or lipoprotein, fatty acids can pass through the sarcolemmal membrane by 
diffusion or a facilitated transport mechanism. In the past it has been 
proposed and believed that passive diffusion account for the uptake 
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 mechanism. However, absent uptake of BMIPP in a small minority of 
patients even without significant cardiac abnormality raised the question 
about the mechanism of fatty acid transport into the cells [3, 4]. It has been 
proved that the patients with deficient myocardial uptake of BMIPP 
correspond to the patients with type I CD36 deficiency (neither platelets nor 
monocytes expresse CD36) [5-7], and biopsy specimen from the patients 
with absent myocardial BMIPP uptake and type I CD36 deficiency 
demonstrated no expression of CD36 on the myocardial capillary endothelial 
cells [8]. PET study demonstrated that the patients without BMIPP cardiac 
uptake showed compensatory increased FDG uptake [9, 10]. Furthermore, 
the absent myocardial BMIPP uptake is hereditable [3] and several gene 
abnormalities related to CD36 deficiency have been reported [11, 12]. Based 
on these clinical data and other animal experiments, it has been proved that 
CD36 plays a crucial role in fatty acid transport into the cells [13]. 
Intracellularly, fatty acids are activated as acyl-CoAs and are consequently 
trapped inside the cell. This process requires one molecule of 
adenosine-5'-triphosphate (ATP) for each fatty acid. Then the acyl-CoAs are 
taken up by mithochondria via an acyl carnitine carrier system and is rapidly 
catabolized by ß-oxidation into 2-carbon fragments, acetyl-CoAs, which 
enter the TCA cycle for further oxidation to become water and carbon 
dioxide. The half-life of ß-oxidation is fast and in the order of minutes but is 
dependent on the adequate oxygen availability. The remaining part of the 
total fatty acid entering the myocyte is incorporated into the lipid pool, 
mainly in the form of triglycerides and phospholipids, or into myocardial 
structural lipids and presents in the myocardium for a long time. Turnover in 
the lipid pool is much slower with the half-life of the order of hours. 
 
Development of iodinated fatty acid compounds for SPECT (Table. 1) 
In mid 1970’s, several iodinated long chain fatty acids were developed by 
introducing radioiodine to the terminal position of fatty acids without 
altering extraction efficiency compared with the natural compound [14-16]. 
These straight chain fatty acids, 123I-hexadecanoic acid (IHXA) and 123I 
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 -heptadecanoic acid (IHDA) were proved to be an indicator of myocardial 
perfusion in canine model and human [15, 16]. After rapid initial myocardial 
extraction these traces showed biexponential clearance (rapid and slow 
components) similar to that of 11C-palmitate. It was generally thought that 
the rapid and slow components of clearances represented ß-oxidation of fatty 
acids and fatty acids storage in lipid pool, respectively. However, their 
ability to assess myocardial metabolism has been questioned. A canine study 
revealed that myocardial counts peaked at 5 min after 131I-IHDA infusion to 
the left atrium followed by decrease with a half life of 36 min, although, the 
myocardial activity of radiolabeled fatty acids remained constant after an 
initial increase, indicating that washout rate of radioactivity from the heart is 
determined by the back diffusion of deiodinated free iodine not by 
ß-oxidation [17]. A clinical study using IHDA demonstrated high quality 
image early after injection, but the image quality deteriorated rapidly 
because of rapid reduction of myocardial counts and increase in background 
counts by deiodinated radioiodine [18]. Accordingly, these characteristics of 
the tracers make IHDA and IHXA unattractive for clinical use, especially for 
SPECT study. To overcome the problem of these alkyl fatty acids, including 
release of free iodine resulting in a rapid loss of image quality and poor 
dependency of elimination rate on ß-oxidation, the phenyl fatty acid was 
developed by attaching iodide to the para position of phenyl ring (IPPA) [19]. 
Because this agent demonstrated high myocardial uptake and no essential 
release of free radioiodide into circulation, the image quality was excellent. 
Animal experiment demonstrated that the IPPA accumulated rapidly to 
myocardium followed by a two-component tracer clearance similar to 
14C-palmitate, permitting estimation of metabolic rate [20]. The uptake of 
IPPA during exercise was related to myocardial perfusion and its catabolism 
follows the usual metabolic pathway for ß-oxidation [21]. Through 
ß-oxidation IPPA is metabolized to iodobenzoic acid and its metabolite 
iodohippurate and these are rapidly excreted from the kidneys with the 
iodine still attached, resulting in high image quality with low background by 
preventing the buildup of free radioiodide [22]. Coronary occlusion and 
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 reperfusion blunted the uptake of IPPA and prolonged the clearance, but 
permanent coronary occlusion decreased the uptake significantly and 
accelerated the clearance, indicating that the IPPA can be used to localize the 
area of myocardial ischemia and infarction [23]. For routine clinical use, 
however, the rate of metabolism and clearance of IPPA is still relatively fast 
for SPECT imaging, even in multiple detector SPECT system. For initial 
IPPA uptake imaging, acquisition time should be shortened to prevent 
progressive undersampling due to rapid count decrease from the 
myocardium, resulting in the deterioration of image quality, and dynamic 
SPECT study may be necessary for kinetic analysis of ß-oxidation. 
Accordingly, a new fatty acid tracer with more prolonged cardiac retention 
has been developed to improve quantitative image quality. For this purpose 
methyl branching was introduced at ß-carbon position to slow myocardial 
clearance by inhibiting ß-oxidation, and 2 forms of iodine labeled modified 
fatty acids, 15-p-iodophenyl-3(RS)-methylpentadecanoic acid (BMIPP) and 
15-p-iodophenyl)-3,3-dimethylpentadecanoic acid (DMIPP), has been 
developed [24, 25]. In fasted rats, myocardial half-time value of BMIPP and 
DMIPP greatly increased to 30-45 min and 6-7 hr, respectively,  compared 
with that of IPPA (5-10 min) [25]. In human, DMIPP showed higher liver 
uptake than that of BMIPP (heart/liver ratio was 0.39 ± 0.05 and 1.00 ± 0.12, 
respectively: p<0.001), suggesting that BMIPP is more favorable cardiac 
SPECT agent [26]. Eventually BMIPP has been widely used to investigate 
the clinical significance as well as basic properties, especially in Japan and 
some European countries. Another alternative of branched fatty acid 
analogue is a 15-p-iodophenyl-9(RS)-methylpentadecanoic acid (9MPA) 
[27]. This tracer had been designed to be cleared from myocardium at 
medium rate by introducing a methyl branch at 9th-carbon position, 
permitting conversion  of 9MPA to iodophenyl-3-methyl-nonanoic acid 
(3MNA) after 3 cycles of ß-oxidation, and this water soluble intermediate 
metabolite, 3MNA, is rapidly cleared from the myocardium. Clinical trail of 
this tracer was performed in Japan and abnormal uptake of this tracer was 
well described in patients with chronic ischemic heart disease and acute 
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 coronary syndrome [28-30]. Ability of identifying ischemic region by 9MPA 
is comparative or even better than that by BMIPP [30], however 
unfortunately, this agent was not approved for health care service provided 
by health insurance. 
 
123I-BMIPP 
Basic characteristics of the tracer and mechanism of discordant BMIPP 
uptake less than perfusion tracers: 
Among the various radio-labeled fatty acids, BMIPP has been studied 
extensively in clinical settings as well as in animal experiments. This 
compound is designed for SPECT imaging, which requires long myocardial 
retention of the tracer for good image quality as described previously. 
Clinical importance of fatty acid imaging depends on whether incremental 
information over perfusion tracers can be obtained or not. Accumulated 
clinical experience of BMIPP imaging has demonstrated that discordant 
BMIPP uptake less than perfusion tracers are often observed in various heart 
diseases especially in ischemic heart disease, and this finding may provide a 
key issue for assessing the pathophysiology of the heart condition. Therefore, 
comparison of BMIPP uptake with that of the perfusion tracers is cardinal for 
the interpretation and exploring the clinical utility of BMIPP as a metabolic 
tracer. 
Initial myocardial BMIPP uptake depends on regional perfusion and is 
transported into myocardial cells via fatty acid translocase/ CD36 
involvement [5, 6, 8, 11-13], followed by a rapid incorporation into 
triglycerides through the enzymatic conversion to BMIPP-CoA [25, 31]. 
Canine study revealed that BMIPP first pass extraction is rather high and 
74% of BMIPP is extracted from plasma into the myocardium within 30 sec 
of intracoronary BMIPP infusion, followed by a small fraction of washout 
(8.7% of infused BMIPP) for the next 30 min [32]. The washed out 
radioactive metabolites consist of backdiffused BMIPP (24% of all washed 
out radioactivity), α oxidation metabolite (27%), intermediate metabolites 
(33%), and full metabolite (16%), suggesting only small amount of 
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 BMIPP-CoA transported into mitochondria is metabolized by α oxidation 
(because first ß oxidation is blocked by ß-methyl branching), followed by ß 
oxidation. The high uptake and low washout of the tracer indicates that 
BMIPP can be substantially considered as a metabolically trapped tracer like 
FDG. Early washout from the myocardium may reflect back diffusion of non 
metabolized BMIPP. Severe ischemia with 30min coronary occlusion and 
reperfusion increased early back diffusion of nonmetabolized BMIPP from 
25.1% to 34.7%, and in mild ischemia (10 min occlusion) back diffusion of 
BMIPP was closely correlated with lactate production (marker of ischemic 
severity) [33]. Etomoxir, one of the carnitine palmotoyltransferase I inhibitor 
and inhibits the transport of long chain lipids into the mitochondria, 
enhanced early washout (until 8 min after injection) of radioactivity due to 
increased back diffusion of BMIPP (25.1% to 41.9%) [34]. These authors 
speculate that this early 8 min washout period in dogs might correspond to 
usual SPECT initiation time in human (around 15 to 20 min after injection of 
BMIPP). If so, clinical BMIPP SPECT image represents the BMIPP 
retention status after the completion of the non metabolized BMIPP back 
diffusion. In the first step of the common pathway of fatty acid metabolism 
BMIPP also converted to BMIPP-CoA by consuming ATP and once 
BMIPP-CoA is synthesized, it is hard to back out of the cell [35, 36]. 
Therefore, ATP level of the cells may relate to the amount of BMIPP back 
diffusion, in other word, BMIPP myocardial retention. BMIPP uptake 
correlated with the ATP level in mouse myocardium treated with an electron 
transport uncoupler, dinitrophenol, which reduced intracellular ATP level 
without affecting acyl-CoA synthetase activity or Coenzyme-A level [37]. In 
acutely damaged canine myocardium introduced by coronary occlusion and 
reperfusion, BMIPP uptake also correlated with the tissue ATP levels [38]. 
In a clinical study with dynamic SPECT demonstrated that the BMIPP 
washout was observed early after BMIPP injection (2-6 min after injection) 
in the segments with reversible thallium defects but not in the segments with 
normal thallium uptake and fixed thallium defects [39]. In addition, early 
dynamic BMIPP SPECT images in acute coronary syndrome showed similar 
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 BMIPP uptake with thallium in spite of the discordant BMIPP uptake less 
than thallium in usual 30 min BMIPP images [40]. These clinical and animal 
experimental findings suggest that, in ischemic myocardium, initial 
myocardial distribution of BMIPP may represent blood flow, followed by a 
back diffusion of free BMIPP which is not incorporated into triglyceride 
pool after conversion to BMIPP-CoA, resulting in discordant BMIPP uptake 
less than thallium on the static images obtained 20-30 min after BMIPP 
injection. 
On the contrary, during acute phase of ischemia, reduced availability of 
oxygen suppresses ß-oxidation and increases the proportion of fatty acid in 
the triglyceride pool. At this moment BMIPP may enter into this enlarged 
triglyceride pool. Accordingly, BMIPP uptake may possibly be  increased in 
acute ischemia [41, 42]. In early canine experiments with occlusion and 
reperfusion model showed higher BMIPP uptake than thallium (reverse 
mismatch) which is an opposite finding observed in clinical studies [41, 43].  
BMIPP injection after 15 or 60 min coronary occlusion and 3 hr reperfusion 
demonstrated that BMIPP uptake in TTC-positive areas was 27% higher 
than in TTC-negative areas and 9 % higher than in normal area after the 
normalization by perfusion, suggesting that greater BMIPP uptake than 
perfusion at acute phase of post-ischemia are characteristic of ischemically 
stunned but viable myocardium [41]. However, BMIPP uptake may change 
as a function of time after ischemia. A recent rat study with 20 min coronary 
occlusion and reperfusion demonstrated that BMIPP uptake was higher than 
thallium at 1 day after reperfusion but, at 5 day after reperfusion, BMIPP was 
similar to or lower than thallium uptake [44]. In addition, another rat study 
with 20 min coronary occlusion and reperfusion revealed that BMIPP uptake 
was higher than thallium at 20 min and 1 day after reperfusion, followed by 
similar uptake at 3 days after reperfusion and significant reduction of BMIPP 
uptake than thallium at 7 days after reperfusion, though, BMIPP uptake 
recovered to normal level at 30 days after reperfusion [45]. Furthermore, 
clinical study in patients with stunned myocardium showed BMIPP uptake 
reduction in area at risk was minimal within 27 hr of onset followed by 
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 significant reduction at 5 to 12 days later, but normalized at 1 month later 
[46]. These findings indicate that BMIPP imaging may offer metabolic 
information independent of perfusion at different stages of ischemic insults 
after ischemia. Usual mismatch, discordant BMIPP uptake less than 
perfusion tracers, seen in clinical study may reflect the myocardial alteration 
of subacute phase of ischemia or cumulative or chromic ischemic status. 
Although most of the discrepant uptake of BMIPP and perfusion tracers in 
daily clinical practice is less BMIPP uptake than perfusion tracers, less 
perfusion tracer uptake than BMIPP (reverse mismatch) can be observed 
occasionally. In normal subjects % uptake of BMIPP is higher than thallium 
in septum to inferior wall [47] and most of the reverse mismatch is observed 
in inferior septum to inferior wall in patients with coronary artery disease 
[48-50], suggesting that reverse mismatch in these area might be generated 
by the greater photon attenuation of thallium than 123I. Such artifact might be 
reduced by using 99mTc labeled perfusion tracers instead of thallium and the 
effectiveness of scatter correction for accurate comparison of BMIPP and 
99mTc-MIBI is proposed [51].  
 
Clinical Utility of 123I-BMIPP imaging 
Acute myocardial infarction 
   In patients with coronary artery disease, discrepant uptake between 
BMIPP and thallium has been reported initially in patients with acute 
myocardial infarction. Tamaki et al. found discordant BMIPP uptake less 
than thallium in 17 of 28 patients with myocardial infarction. Such 
discordant BMIPP uptake was observed more often in areas of acute than 
chronic myocardial infarction (59% at <4 week versus 31% at >4 week after 
onset), and more often in areas supplied with revascularized than 
non-revascularized arteries (74% versus 28%, respectively). In addition, 
regional wall motion was more severely impaired in such 
perfusion-metabolic mismatching area [50]. In comparison between BMIPP 
and 99mTc-MIBI 4 to 10 days after coronary thrombolysis demonstrated that 
the segments with more reduced BMIPP uptake than MIBI uptake 
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 (mismatching) showed either normal wall motion or demonstrated inotropic 
reserve during dobutamine stimulation [52]. These findings suggested that 
mismatching is indicative of jeopardized but viable myocardium and may 
correspond to stunned myocardium where functional abnormality is 
prolonged in association with sustained metabolic abnormalities 
(metabolically stunned myocardium) after perfusion recovery by successful 
reperfusion procedures (Fig. 1). Several studies have supported this concept, 
that is, areas of discordant BMIPP uptake less than perfusion tracers in acute 
or subacute stages of myocardial infarction demonstrated improvement of 
wall motion abnormality on the subsequent follow-up periods [53-60]. 
These studies also indicated that mismatched BMIPP uptake less than 
perfusion tracers may be a predictor of functional recovery in acute 
myocardial infarction. For the evaluation of area at risk in acute myocardial 
infarction, reduction of BMIPP uptake is also shown to be useful. BMIPP 
defect size in subacute phase of myocardial infarction correlated well with 
the risk area revealed by contrast ventriculography or echocardiography [56, 
61], and the area with BMIPP reduction 1 week after the onset of myocardial 
infarction corresponded well to the area with perfusion defect which was 
demonstrated before revascularization therapy at admission [62]. These 
observations suggested that BMIPP imaging obtained in subacute phase of 
myocardial infarction can be called “ischemic memory imaging” because it 
reflects prior ischemic damage or metabolically stunned myocardium even 
after the restoration of perfusion abnormality [56, 63, 64].  
In chronic phase of myocardial infarction, mismatched uptake of BMIPP 
less than thallium is not an uncommon finding. The study compared resting 
BMIPP uptake and exercise-redistribution thallium scintigraphy in 26 
patients with prior myocardial infarction (>4 week after onset) without 
revascularization therapy demonstrated that 67% of the segments with 
discordant BMIPP uptake less than redistribution thallium showed reversible 
thallium defects, 21% showed fixed thallium defects and 12% showed 
normal thallium uptake, indicating that the myocardium with mismatched 
BMIPP uptake less than redistribution thallium uptake were mostly exposed 
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 to stress induced ischemia [39]. In subacute to chronic phase of infraction 
(>2 week after onset), similar findings were reported, with most of the 
mismatched segments (22/27) is associated with reversible thallium defect 
[65]. 
 
Unstable angina pectoris 
In patients with unstable angina, mismatched BMIPP uptake less than 
thallium has also been observed frequently [66-69]. Comparison of BMIPP 
image in 19 patients with unstable angina without prior myocardial 
infarction and stress thallium scan performed after stabilization of their 
condition demonstrated that BMIPP decrease was associated with stress 
perfusion abnormality in 44 of 57 (77%) segments and degree of BMIPP 
reduction correlated with the degree of perfusion abnormality at stress, 
degree of wall motion abnormality, and severity of coronary artery stenosis 
[66]. BMIPP imaging performed in 20 patients with unstable angina after 
medication and elimination of chest pain disclosed that patients with 
abnormal BMIPP uptake (n=11) had more severe coronary artery stenosis 
exceeding 90% (10/11 vs 4/9), 99% stenosis (9/11 vs 0/9) and more 
collateral opacification (4/11 vs 0/9) than patients without BMIPP 
abnormality (n=9). In addition, revascularization was performed in 82% of 
patients with abnormal BMIPP images, while in only 22% of patients with 
normal BMIPP images, accordingly, BMIPP imaging may be helpful in 
decision-making for interventional treatment [68]. In a study of 111 
consecutive patients with acute chest pain without myocardial infarction, 
BMIPP (performed 2 days after chest pain) abnormality was observed in 
74% of coronary abnormalities, while only 38% showed tetrofosmin (within 
24 hr after chest pain) abnormality [70]. These findings indicate that reduced 
BMIPP uptake in patients with unstable angina may represent persistent 
metabolic abnormality reflecting prior severe ischemia or repetitive 
ischemic insults, thus the concept of ischemic memory imaging could be 
extended and applied to these patients population. In other words, BMIPP 
imaging could extend time window for detecting previous ischemic event 
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 after the resolution of perfusion abnormality. In addition, ischemic memory 
concept can be applied to the patients with vasospastic angina pectoris. In 
the patients repetitive ischemia may cause metabolic alteration and this 
metabolic alteration can be detected as a reduction of BMIPP uptake, 
however, stress perfusion SPECT often failed to detect ischemia because 
exercise or vasodilator stress usually does not provoke vasospasm. 
Accordingly, BMIPP imaging should be considered as one of the 
noninvasive diagnostic methods [71]. 
 
Chronic coronary artery disease 
In chronic stable coronary artery disease even without history of myocardial 
infarction, discordant BMIPP uptake less than perfusion tracer is not a rare 
finding (Fig. 2). Comparison between BMIPP uptake and stress-reinjection 
thallium SPECT in 45, patients with chronic coronary artery disease 
demonstrated that most of the segments (118/124) with discordant BMIPP 
uptake less than reinjection-thallium were associated with reversible 
thallium defects, indicating ischemic myocardium [48]. When reversible 
thallium defects were analyzed, 118 out of 237 segments evidenced 
discordant BMIPP uptake less than reinjection thallium, suggesting that 
approximately half of the segments with ischemic myocardium have more 
severe metabolic abnormality than expected from the degree of resting 
perfusion abnormality.  On the other hand, 71 (79%) of 90 segments with 
fixed thallium defects demonstrated concordant uptake of both tracers, 
suggesting myocardium with poor viability has metabolic abnormality 
similar to the degree of resting perfusion abnormality.  When reversible 
thallium defects were analyzed with respect to the evidence of discordant 
BMIPP uptake less than thallium and regional wall motion abnormality, wall 
motion was more severely impaired in the segments with discordant BMIPP 
uptake less than thallium than those without such discordance in both subset 
of patients with and without old myocardial infarction. However, severity of 
coronary artery stenosis was similar in the vascular teritory with discordant 
BMIPP uptake less than reinjection thallium and those without such 
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 discordance. Similar findings were also reported in 12 patients with stable 
angina without prior myocardial infarction, with location and degree of 
BMIPP decrease was associated with those of stress-induced hypoperfusion 
on thallium imaging, but no significant correlation between BMIPP 
reduction and coronary artery stenosis was found [66]. In 55 patients with 
stable coronary artery disease who had persistent thallium defects in at least 
one segment on stress-redistribution thallium imaging,  BMIPP uptake in the 
segments with new fill-in after thallium reinjection was investigated [72]. 
Discordant BMIPP uptake less than thallium was observed in 37% of the 
segments with thallium redistribution after exercise, on the contrary, such 
discordance was observed in 82% of the segments with no redistribution but 
new fill-in after thallium reinjection. In addition, such discordance was 
observed in only 19% of the segments with fixed defects. In previous studies 
using stress-redistribution-reinjection thallium, the myocardium with new 
fill-in after thallium reinjection is characterized as severely ischemic but 
viable myocardium with frequent wall motion abnormalities that may 
recover after revascularization [73, 74]. Accordingly, these observation may 
indicate that mismatched uptake is suggestive of the myocardium 
jeopardized by more severe ischemia. 
The concept of ischemic memory imaging of BMIPP has been tested in 32 
patients with exercise-induced ischemia on thallium SPECT by injecting 
BMIPP at rest within 30 hrs of ischemia which was induced and confirmed 
by exercise thallium SPECT [75]. In more than 90 % of patients, BMIPP 
identified suppressed fatty acid uptake area corresponding to the ischemia 
detected by stress thallium study up to 30 hrs after ischemic episode, 
therefore, the authors concluded that BMIPP can identify sustained 
metabolic abnormality as a ischemic memory imaging at least until 30 hrs 
after stress induced ischemic episodes. Accumulated data in patients with 
chronic ischemic heart disease in Japan, however, demonstrated that reduced 
BMIPP uptake was frequently observed independent of prior radionuclide 
and ECG stress tests but related to severe ischemia and wall motion 
abnormality, raise the possibility that BMIPP reduction reflects the substrate 
 13
 shift from fatty acid to glucose as a results of repeated myocardial ischemia 
rather than reflecting the single episode of metabolic stunning. Myocardium 
exposed to repetitive ischemia or stunning is subsequently adapted 
metabolically into chronic ischemic myocardium, so called hibernation 
[76-78]. In hibernating myocardium, energy substrate is shifted from fatty 
acid to glucose, contractility is impaired but with recruitable inotropic 
reserve, and myocardial flow reserve is severely impaired. In relation to this 
issue, recent investigation of the relationship between BMIPP uptake and 
myocardial blood flow measured by PET in patients with chronic stable 
angina without previous myocardial infarction demonstrated that rest 
myocardial blood flow was preserved independent of BMIPP uptake. 
However, hyperemic myocardial blood flow was decreased in the area with 
reduced BMIPP uptake, resulting in the severity of impaired myocardial 
flow reserve correlated to the reduction of BMIPP uptake [79]. Hence, 
reduced BMIPP uptake implies impaired myocardial flow reserve and may 
reflects substrate shifts in hibernating myocardium. 
 
Viability assessment and prediction of functional recovery in chronic 
coronary artery disease 
Improvement of regional or global systolic function can be achieved if 
revascularization of viable myocardium is successfully performed. 
Therefore, assessment of residual myocardial viability in the setting of 
dysfunctional myocardium due to significant coronary artery disease is a key 
issue in making clinical decisions with respect to revascularization 
procedures.  On scintigraphy using perfusion tracers, the hallmarks of 
myocardial viability supplied by a stenosed or occluded coronary artery are 
the perfusion defect with thallium redistribution on stress-redistribution or 
rest-redistribution images, fill-in of thallium, setamibi, and tetrofosmin after 
reinjection, or significant uptake on resting or reinjection images (usually 
more than 50-60% uptake of normal area).  However, the ability of perfusion 
tracers to differentiate viable from non-viable myocardium is not completely 
satisfactory as evidenced by recent viability studies using perfusion tracers 
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 [80, 81]. 
In chronic coronary artery disease, the hallmark of viability of perfusion 
tracers is the significant tracer uptake, although, the hallmark of viability in 
BMIPP imaging is the relative reduction of BMIPP uptake compared to 
perfusion tracers. There are several substantial evidences that discordant 
BMIPP uptake less than perfusion tracers is a marker of viability. Firstly, as 
previously described, such mismatch is associated with ischemic 
myocardium as evidenced by stress perfusion studies. Secondly, increased 
FDG uptake was observed in areas with discordant BMIPP uptake less than 
thallium and higher oxidative metabolism by11C-acetate PET was observed 
in mismatched area than the area with concordant reduction of BMIPP and 
perfusion [82]. Thirdly, myocardial areas with BMIPP uptake less than 
sestamibi were more likely to have a positive response to dobutamine than 
areas with matched defect [83, 84]. Lastly, histologic examination in patients 
with bypass surgery demonstrated that BMIPP uptake reduction against % 
fibrosis looked biphasic, with steep reduction of BMIPP uptake within 20% 
of fibrosis, although, thallium uptake reduction correlated linearly to % 
fibrosis. Thus, the areas with discordant BMIPP uptake less than thallium 
had less than 20% fibrosis [85].  
More directly, functional recovery after revascularization has been 
investigated in relation to BMIPP uptake abnormality. In patients with 
chronic stable coronary artery disease, discordant BMIPP uptake less than 
thallium could predict functional recovery after revascularization more 
precisely than exercise-reinjection thallium study. In addition, the extent of 
discordant uptake of BMIPP less than reinjection thallium before 
revascularization were a good predictor of global ejection fraction 
improvement after revascularization [86]. Similarly, in patients with chronic 
ischemic left ventricular dysfunction, area with discordant BMIPP uptake 
less than sestamibi measured by quantitative analysis was highly predictive 
of improvement of ejection fraction, wall motion and free fatty acid 
utilization after revascularization [84]. Interestingly, the comparison of FDG, 
BMIPP, and sestamibi uptake in patients with old myocardial infarction and 
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 stable ischemic regional wall motion abnormalities demonstrated that extent 
of discordant BMIPP uptake less than FDG uptake before revascularization 
highly correlated with ejection fraction improvement after revascularization 
(r = 0.74) and also the extent of discordant BMIPP uptake less than sestamibi 
correlated significantly with ejection fraction improvement (r = 0.50). 
However, no significant correlation was observed between the area with 
discordant FDG uptake more than sestamib and ejection fraction recovery 
[87]. The results are quite intuitive because, in ischemic and viable 
myocardium, substrate shift from fatty acid to glucose would take place, 
hence, mismatch of FDG and BMIPP uptake should be prominent but 
mismatch between BMIPP and sestamibi might be modest. These data 
suggest that discordant BMIPP uptake less than perfusion may represent 
reversible ischemic myocardial injury or hibernating myocardium and that 
the regional and global dysfunction will improve after revascularization in 
patients with chronic stable coronary artery disease. 
 
Risk stratification and prognostic value 
Assessment of prognostic value of BMIPP imaging over perfusion tracers in 
patients with coronary artery disease is a matter of clinical importance.  The 
initial study in 50 consecutive patients with myocardial infarction was 
performed to investigate the prognostic implications of BMIPP and 
stress-reinjection thallium imaging (obtained at 2 week to 6 month after 
infarction) with a mean follow up period of 23 months [88]. During the 
follow-up period 9 patients had cardiac events and 8 of the 9 patients with 
cardiac events showed discordant BMIPP uptake less than reinjection 
thallium, whereas only 20 of 41 patients without cardiac events did so. When 
all the clinical and radionuclide variables were analyzed by Cox regression 
analysis, presence of discordant BMIPP uptake was the best, and an 
independent, predictor of future cardiac events followed by the number of 
coronary stenosis. BMIPP and thallium imaging performed within 1 month 
of acute myocardial infarction demonstrated that impaired BMIPP uptake 
and mismatched BMIPP uptake less than thallium are related to a high 
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 probability of fatal and non-fatal cardiac events [89] and the defect score of 
BMIPP and mismatched BMIPP uptake less than thallium provided 
incremental predictive value for future cardiac events [90]. In addition 
clinical value of BMIPP imaging is also revealed in the patients with chronic 
stage of myocardial infarction. BMIPP imaging performed before 
revascularization in 76 patients with chronic stable ischemia (including 61 
patients with myocardial infarction after at least 3 month of onset) with left 
ventricular dysfunction has been analyzed [91]. Patients with large amount 
of discordant BMIPP uptake less than thallium demonstrated greater ejection 
fraction improvement after revascularization and, interestingly, showed 
significantly better event free survival than patients with small amount or no 
perfusion and metabolic mismatch.  These data indicate that patients with 
significant amount of discordant BMIPP uptake less than thallium may 
benefit from revascularization. It has been also demonstrated that BMIPP 
imaging is also valuable for risk stratification in chronic coronary artery 
disease without old myocardial infarction. In 270 patients with known or 
suspected coronary artery disease without previous myocardial infarction, 
BMIPP defect score was analyzed with respect to cardiac event during a 
median follow-up of 3.9 years [92]. Kaplan-Meier survival estimates 
revealed a hard event-free survival rate of 98% at 3 years in patients with a 
summed BMIPP defect score lower than 5 but 93% in those with a defect 
score of 5 or greater (P = 0.03) and all event-free survival rate of 92% at 3 
years in patients with a summed BMIPP defect score lower than 5 but 80% in 
those with a defect score of 5 or greater (P = 0.0003). More importantly, 
BMIPP was able to select a high-risk subgroup among patients with diabetes 
mellitus as well as non-diabetic patients, with 41% event rate in diabetic 
patients with BMIPP defect score 5 or more but only 4% event rate in 
non-diabetic patients with BMIPP defect score lower than 5. This ability of 
BMIPP imaging for risk stratification in diabetic patients is advantageous 
against FDG PET imaging, because myocardial BMIPP uptake is not 
affected by blood substrate contents but FDG uptake is influenced 
significantly [93, 94].  Another strength of BMIPP imaging is its simplicity 
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 since it offers metabolic information without stress procedure. It is a matter 
of great interest whether resting BMIPP imaging offers complementary or 
additional prognostic information over conventional stress perfusion 
imaging or not. Consecutive 167 patients with angina pectoris but without 
prior myocardial infarction who had undergone both BMIPP and stress 
thallium imaging were followed up for 48 months [95]. For overall cardiac 
events (5 hard and 29 soft events), multivariate Cox’s analysis revealed that 
reduced BMIPP uptake, stress perfusion score, diabetes, and left ventricular 
ejection fraction were the significant predictors. No hard event was observed 
with normal BMIPP uptake, whereas 2 patients with nearly normal stress 
perfusion with impaired BMIPP uptake had a hard event. The authors 
concluded that resting BMIPP imaging may provide significant prognostic 
information independent of stress myocardial perfusion imaging. 
 
Cardiomyopathy 
   In patients with cardiomyopathy, evaluation of the metabolic status in 
addition to perfusion may offer a clue for the assessment of the underlying 
pathophysiology of the disease.  Animal experiments with autoradiography 
using methyl-branched fatty acids in cadiomyopathic hamsters and 
hypertensive rats demonstrated that fatty acid uptake was heterogeneous and 
lower than thallium in endocardium [96-100].  In patients with 
cardiomyopathy, including hypertrophic cardiomyopathy (HCM) and 
dilated cardiomyopathy (DCM), it has been reported that BMIPP 
distribution is inhomogeneous and discordant BMIPP uptake less than 
thallium is a general finding especially in patients with HCM (Fig. 3). In 
patients with HCM discordant BMIPP uptake less than thallium in the 
disproportionately thickened septum was a common finding [101, 102] and 
mismatched BMIPP uptake less than thallium in the hypertrophied septum 
and the degree of BMIPP abnormality was correlated with the severity of 
hypertrophy [103]. In addition, BMIPP accumulation was significantly less 
in the septal portion of the anterior and the posterior wall and the apex than 
in the lateral segments. The patients with such BMIPP defects in the septal 
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 portion of anterior and posterior segments had a more frequent family 
history of HCM, sudden death, and severe cardiac dysfunction [104] and the 
severity of BMIPP abnormality was a significant predictor of cardiac events 
including heart failure and cardiac death [105, 106]. Several studies 
employing stress thallium scintigraphy in patients with HCM have revealed 
that, despite the normal epicardial coronary arteries, the reversible perfusion 
defect is a commonly seen findings, which could be eliminated by verapamil, 
and that ischemia may account for the phenomenon [107-109]. When the 
relationship between BMIPP uptake and ischemia defined by reversible 
perfusion defect in stress-redistribution thallium scintigraphy in HCM 
patients was investigated, mismatched BMIPP uptake less than thallium in 
hypertrophied areas often accompanied reversible thallium defects [102, 
110]. Furthermore, BMIPP imaging depicts disease associated abnormality 
even at early stages [102].  In 5 patients with NYHA class 1, all patients 
showed normal stress thallium and only 1 showed reduced BMIPP uptake.  
In 6 patients with NYHA class 2, all showed reduced BMIPP uptake less 
than redistribution thallium and 4 showed stress induced ischemia in the 
mismatched area and 2 showed normal thallium findings.  In 6 patients with 
NYHA class 3, all showed reduced BMIPP uptake less than redistribution 
thallium with 4 showing additional matched defect simultaneously and only 
2 showed stress induced ischemia in the mismatched area. Together with 
other recent studies, the discordant BMIPP less than thallium in hypertrophic 
areas with high frequency of reversible thallium defects suggests that 
myocardial ischemia or impaired coronary flow reserve may play a 
considerable role in impaired fatty acid utilization or metabolism [110, 111] 
and that mismatched uptake may be an early marker of HCM followed by 
matched defect at later stage [102]. A recent study with positron emission 
tomography demonstrated that, in patients with HCM, the reduction of 
BMIPP uptake was the most sensitive indicator of metabolic abnormalities 
followed by the abnormal oxidative metabolism and FDG uptake [112]. As 
for the ventricular function in patients with HCM, BMIPP uptake 
abnormality correlated well with regional function and also correlated well 
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 with global ejection fraction, while thallium abnormality did not, hence the 
ventricular function correlated more closely with metabolic abnormality 
than perfusion [113-116]. 
In patients with DCM, both BMIPP and thallium distribution was 
heterogeneous, and BMIPP abnormality correlated well with ventricular 
dysfunction, whereas, thallium abnormality did not [117]. In addition, the 
extent of the BMIPP abnormality reflects the severity of haemodynamic 
deterioration and histopathological changes [118]. BMIPP imaging is useful 
for therapy monitoring and risk stratification in DCM patients. In the therapy 
with ß-blocker, decrease in BMIPP uptake in patients with DCM did not 
respond well to the therapy, however, BMIPP uptake improved after 
ß-blocker therapy in only non-responder, indicating that ß-blocker therapy 
may lead to metabolic improvement even without functional improvement 
[119, 120]. However, controversial results have also been reported. DCM 
patients with reduced BMIPP uptake also did not respond to ß-blocker 
therapy but BMIPP uptake improved in only responders after treatment 
[121]. By the treatment with coenzyme Q10, BMIPP uptake abnormality in 
patients with DCM improved, while the percent fractional shortening 
measured by echocardiography did not changed, suggesting that BMIPP 
imaging could be a more sensitive indicator than functional parameter [122]. 
These data indicates that BMIPP uptake may predict the response to 
ß-blocker therapy in DCM, however, in the monitoring of therapeutic effect, 
role of BMIPP imaging should warrant further investigation.  
BMIPP imaging might provide helpful information for the differential 
diagnosis of patients with severe LV dysfunction. Ischemic cardiomyopathy 
and DCM are the main cause of congestive heart failure and share similar 
clinical features, such as dilated ventricle, diffuse hypokinesis with severely 
reduced ejection fraction. However, the therapeutic approach in both 
diseases is quite different. When discordant BMIPP uptake less than thallium 
is investigated, ischemic cardiomyopathy and dilated form of HCM showed 
high prevalence of mismatched uptake, while idiopathic DCM, alcoholic and 
hypertensive cardiomyopathy showed lower incidence of mismatched 
 20
 uptake [123]. 
Transient left ventricular apical ballooning is a newly defined syndrome in 
Japan and has been called Takotsubo cardiomyopathy or transient left 
ventricular apical ballooning syndrome. It is characterized by sudden onset 
of chest symptoms, electrocardiographic changes, transient left ventricular 
wall motion abnormalities particularly involving in the apical region, 
low-grade cardiac enzyme elevation, and absence of significant coronary 
stenosis [124, 125]. In subacute phase (around 5 days after onset) thallium 
uptake reduction was mild but marked BMIPP uptake reduction was 
observed in the regions with an apical asynergy. Resolution of apical 
asynergy was observed around 15 days after onset, while normalization of 
impaired BMIPP uptake was observed about 1 month after the onset [126]. 
Recent study demonstrated that tetrofosmin uptake immediately after the 
onset was severely depressed in the area that corresponded to the large apical 
dysfunction. The tetrofosmin uptake abnormality and apical dysfunction 
recovered rapidly at subacute stage, but BMIPP abnormality persiste for a 
longer period [127]. These finding suggested that the transient ventricular 
dysfunction in this disease may essentially be stunned myocardium, 
although the etiology is still unknown. 
 
Conclusions 
In normal condition approximately two-thirds or more of the total energy 
produced by myocardium is derived from fatty acid oxidation and 
myocardial substrates may change significantly in various pathological 
conditions such as ischemia. Accordingly, many fatty acid tracers for SPECT 
imaging have been introduced. However, straight chain fatty acid analogue 
has not been used widely in clinical studies because of its rapid washout is 
not suitable for SPECT imaging. On the contrary, methyl branched fatty acid 
analogue permit SPECT imaging more easily because of its prolonged 
myocardial retention. BMIPP, one of the methyl branched fatty acid 
analogues, is the only approved fatty acid tracer for daily clinical use at 
present. The concept of BMIPP imaging is metabolic trapping, like FDG, by 
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 inhibiting ß-oxidation by introducing methyl branching at ß-carbon position. 
Myocardial BMIPP uptake more likely reflects activation of BMIPP into 
BMIPP-CoA and reflects indirectly cellular ATP production by fatty acid 
metabolism. Hence, under the condition of ischemia, the reduction of 
BMIPP uptake is observed by reflecting the reduction of ATP production due 
to depressed oxidative fatty acid metabolism and substrate shift from fatty 
acids to glucose. Reduced utilization of fatty acids or reduced uptake of 
BMIPP at rest is often observed in ischemic myocardium independent of the 
uptake of perfusion tracers. Through comparison with perfusion, BMIPP 
image can detect previous myocardial ischemia as an ischemic memory 
imaging (stunned myocardium) and viable but chronically dysfunctional 
myocardium (hibernating myocardium). In addition, BMIPP image may 
offer incremental prognostic information in ischemic heart disease. In 
cardiomyopathy, BMIPP imaging may be useful for the early detection of 
HCM and differentiation of ischemic cardiomyopathy from idiopathic DCM, 
and also for the prediction of prognosis. Through the basic and clinical 
studies, it has become clear that BMIPP imaging has a high potential utility 
in clinical nuclear cardiology practice. Thus world wide clinical use of fatty 




 Figure legends 
 
Fig. 1. 
Short-axis slices and horizontal long axis slices of 99mTc-tetrofosmin, 123I- 
BMIPP and gated blood pool images. Patient was admitted with acute 
myocardial infarction (AMI) and emergency coronary angiography revealed 
90% stenosis of the proximal left anterior descending coronary artery. Direct 
angioplasty was performed successfully. Maximum creatine kinase was 460 
IU/L. Gated blood pool study demonstrated severe hypokinesis of apex to 
anteroseptal wall at 3 days after the onset. 6 days after the onset of AMI, 
tetrofosmin did not show definite perfusion abnormality, though, reduced 
BMIPP uptake was noted in the anteroseptal wall. 3 month later BMIPP 
uptake improved and wall motion abnormality disappeared. The area with 
discordant BMIPP uptake less than perfusion may represent metabolically 




Horizontal long axis and sagittal slices of 201Tl, 123I- BMIPP and gated blood 
pool images. The patient with diabetes mellitus and nephrotic syndrome had 
electrocardiographic abnormality, therefore, the thallium and BMIPP 
SPECT were performed. Discordant BMIPP uptake less than thallium in 
apex to anteroseptal wall was observed and the area demonstrated severe 
hypokinesis in gated blood pool scintigraphy. Coronary angiography showed 
left anterior descending coronary artery (LAD) obstruction and 90% stenosis 
of the left circumflex coronary artery. Coronary angioplasty of the LAD was 
performed successfully and BMIPP uptake and wall motion abnormality 
improved 1 month later. The discordant BMIPP uptake less than thallium 
depicted the dysfunctional but viable myocardium or hibernating 




 Sagittal, horizontal long axis and short axis slices of 201Tl, 123I- BMIPP in 
patients with hypertrophic cardiomyopathy (HCM). Thallium demonstrated 
increased uptake in apex to anteroseptal wall, but BMIPP uptake showed 
reduction of uptake in the area. Discordant BMIPP uptake less than thallium 
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